130 related articles for article (PubMed ID: 14666706)
1. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.
Cummings J; Ritchie A; Butler J; Ward TH; Langdon S
Anticancer Res; 2003; 23(5A):3979-83. PubMed ID: 14666706
[TBL] [Abstract][Full Text] [Related]
2. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
3. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
4. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Digby T; Leith MK; Thliveris JA; Begleiter A
Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
[TBL] [Abstract][Full Text] [Related]
5. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.
Malkinson AM; Siegel D; Forrest GL; Gazdar AF; Oie HK; Chan DC; Bunn PA; Mabry M; Dykes DJ; Harrison SD
Cancer Res; 1992 Sep; 52(17):4752-7. PubMed ID: 1324793
[TBL] [Abstract][Full Text] [Related]
6. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
7. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity.
Gibson NW; Hartley JA; Butler J; Siegel D; Ross D
Mol Pharmacol; 1992 Sep; 42(3):531-6. PubMed ID: 1406604
[TBL] [Abstract][Full Text] [Related]
8. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ.
Nemeikaite-Ceniene A; Dringeliene A; Sarlauskas J; Cenas N
Acta Biochim Pol; 2005; 52(4):937-41. PubMed ID: 15940348
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
Ward TH; Danson S; McGown AT; Ranson M; Coe NA; Jayson GC; Cummings J; Hargreaves RH; Butler J
Clin Cancer Res; 2005 Apr; 11(7):2695-701. PubMed ID: 15814651
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Loadman PM; Phillips RM; Lim LE; Bibby MC
Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
[TBL] [Abstract][Full Text] [Related]
11. Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial.
Danson S; Ranson M; Denneny O; Cummings J; Ward TH
Cancer Chemother Pharmacol; 2007 Nov; 60(6):851-61. PubMed ID: 17333193
[TBL] [Abstract][Full Text] [Related]
12. Mapping of DNA alkylation sites induced by aziridinylbenzoquinones in human cells by ligation-mediated polymerase chain reaction.
Lee CS; Pfeifer GP; Gibson NW
Cancer Res; 1994 Apr; 54(7):1622-6. PubMed ID: 8137269
[TBL] [Abstract][Full Text] [Related]
13. Increased NAD(P)H:(quinone-acceptor)oxidoreductase activity is associated with density-dependent growth inhibition of normal but not transformed cells.
Schlager JJ; Hoerl BJ; Riebow J; Scott DP; Gasdaska P; Scott RE; Powis G
Cancer Res; 1993 Mar; 53(6):1338-42. PubMed ID: 8443814
[TBL] [Abstract][Full Text] [Related]
14. Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model.
Wu K; Eng E; Knox R; Chen S
Arch Biochem Biophys; 2001 Jan; 385(1):203-8. PubMed ID: 11361019
[TBL] [Abstract][Full Text] [Related]
15. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
Begleiter A; Leith MK; Curphey TJ; Doherty GP
Oncol Res; 1997; 9(6-7):371-82. PubMed ID: 9406243
[TBL] [Abstract][Full Text] [Related]
16. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
17. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs.
Powis G; Gasdaska PY; Gallegos A; Sherrill K; Goodman D
Anticancer Res; 1995; 15(4):1141-5. PubMed ID: 7653992
[TBL] [Abstract][Full Text] [Related]
18. The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.
Kim JY; Patterson AV; Stratford IJ; Hendry JH
Anticancer Drugs; 2004 Jan; 15(1):71-7. PubMed ID: 15090746
[TBL] [Abstract][Full Text] [Related]
19. Cigarette smoking is a determinant of DT-diaphorase gene expression in human non-small cell lung carcinoma.
Gasdaska PY; Powis G; Hyman P; Fisher H
Cancer Res; 1993 Nov; 53(22):5458-61. PubMed ID: 8221686
[TBL] [Abstract][Full Text] [Related]
20. DT-diaphorase: a target for new anticancer drugs.
Danson S; Ward TH; Butler J; Ranson M
Cancer Treat Rev; 2004 Aug; 30(5):437-49. PubMed ID: 15245776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
